Category Archives: Thyroid

Thompson L.

Ear Nose Throat J. 2006 Aug;85(8):480, 483.

FIRST PARAGRAPH: Tumors that occur in the thyroid gland as a result of lymph or vascular spread from distant sites are considered to represent metastatic disease rather than a direct extension of a primary from an adjacent organ. Metastatic deposits are identified at a higher frequency in abnormal glands—that is, those with adenomatoid nodules, thyroiditis, and follicular neoplasms. Further, metastatic deposits may be found within primary thyroid tumors, such as a renal cell carcinoma metastatic to a thyroid papillary carcinoma. Although a thyroid gland mass may be the presenting clinical sign, it is more often the underlying thyroid gland disease (e.g., thyroiditis, adenomatoid nodules) that prompts clinical evaluation. The thyroid gland metastatic deposit is the initial presentation of an occult primary tumor in as many as 40% of patients. Carcinomas are the most common metastatic tumors from (in order of frequency) the kidney (figure 1), lung, breast (figure 2), and stomach; melanoma is less common.

PubMed ID: 16999049

Article Size: <1 MB

Thompson LD.

Ear Nose Throat J. 2017 Feb;96(2):54-55.

FIRST PARAGRAPH: Embryologically, the thyroglossal duct develops as the thyroid anlage descends from the foramen cecum at the base of the tongue to its final resting point in the pretracheal inferior midline neck. The duct usually involutes, but persistence may give rise to a clinical cyst. Thyroglossal duct remnant cysts (TGDCs) are one of the most common neck lesions seen clinically, showing a bimodal age distribution in the first and fifth decades, and identified in approximately 2.2/100,000 population at risk each year. While there is an equal sex distribution, males tend to predominate in pediatric patients while females predominate among adults.

PubMed ID: 28231361

Article Size: <1 MB

College of American Pathologists (CAP)

Protocol applies to all carcinomas of the thyroid gland. Lymphomas, sarcomas and metastases are not included.

Based on AJCC/UICC TNM, 7th edition
Protocol web posting date: October 2009
Protocol effective date: January 2010

Article Size: 1 MB

Chiosea S, Asa SL, Berman MA, Carty SE, Currence L, Hodak S, Nikiforov YE, Richardson MS, Seethala RR, Sholl LM, Thompson LD, Wenig BM, Worden F; Members of the Cancer Biomarker Reporting Committee, College of American Pathologists.

Arch Pathol Lab Med. 2017 Apr;141(4):559-563.

The College of American Pathologists offers these templates to assist pathologists in providing clinically useful and relevant information when reporting results of biomarker testing. The College regards the reporting elements in the templates as important elements of the biomarker test report, but the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these templates as educational tools to assist pathologists in the useful reporting of relevant information. It did not issue them for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the templates might be used by hospitals, attorneys, payers, and others. The College cautions that use of the templates other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

Completion of the template is the responsibility of the laboratory performing the biomarker testing and/or providing the interpretation. When both testing and interpretation are performed elsewhere (e.g., a reference laboratory), synoptic reporting of the results by the laboratory submitting the tissue for testing is also encouraged to ensure that all information is included in the patient’s medical record and thus readily available to the treating clinical team.

PubMed ID: 27681332

Article Size: 83 KB